Sun Pharmaceutical Industries and Ranbaxy (UK) v Commission

JUDGMENT OF THE COURT (Fourth Chamber)25 March 2021(*)[Text rectified by order of 3 September 2021](Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressant medicines (citalopram) – Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine )In Case C‑586/16 P,APPEAL under Article 56 of the Statute of the Court of Justice of the European Union, brought on 17 November 2016,Sun Pharmaceutical Industries Ltd, formerly Ranbaxy Laboratories Ltd, established in Vadodara (India), Ranbaxy (UK) Ltd, established in Hayes (United Kingdom), represented by R. Vidal, Solicitor, and B. Kennelly QC, and by L. Penny, Solicitor,appellants,the other parties to the proceedings being:[As rectified by order of 3 September 2021] European Commission, represented by F. Castilla Contreras, T. Vecchi, B. Mongin and C. Vollrath, acting as Agents, and by D. Bailey, Barrister,defendant at first instance,supported by:United Kingdom of Great Britain and Northern Ireland, represented initially by D. Guðmundsdóttir, Z. Lavery and D. Robertson, acting as Agents, and by J. Holmes QC, and subsequently by D. Guðmundsdóttir, acting as Agent, and by J. Holmes QCintervener in the appeal,THE COURT (Fourth...